NCT04769297View on ClinicalTrials.gov

Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

PHASE4UnknownINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions

Acute Stress Disorder

Interventions

DRUG

Sublingual Micro-Dose Ketamine

daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic

Trial Locations (1)

91602

Limbic Medical, Toluca Lake

Sponsors

Lead Sponsor

Collaborators (1)

Enovex Pharmacy

All Listed Sponsors

collaborator

Enovex Pharmacy

UNKNOWN

lead

Limbic Medical

OTHER

NCT04769297 - Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic | Biotech Hunter | Biotech Hunter